GlassScriptPhysician profile
Lena Liu
NPI 1730830662
$3,774.74
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,155 · 2023: $1,604 · 2024: $15.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $667.05 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $482.17 | 2022-2023 | Austedo Xr, Austedo, Uzedy |
| Otsuka America Pharmaceutical, INC. | $422.24 | 2022-2023 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $370.85 | 2022-2023 | Lybalvi, Aristada |
| Corium, LLC | $291.76 | 2022-2023 | Azstarys |
| Neurocrine Biosciences, INC. | $181.89 | 2022-2023 | Ingrezza |
| Lundbeck LLC | $180.52 | 2022-2023 | Abilify Maintena, Brintellix |
| Sunovion Pharmaceuticals INC. | $159.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.85 | 2022-2023 | Trintellix |
| Supernus Pharmaceuticals, INC. | $142.67 | 2022-2024 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $142.45 | 2022-2023 | Caplyta |
| Ironshore Pharmaceuticals INC. | $101.12 | 2022-2023 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $99.76 | 2022-2023 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $80.44 | 2022-2023 | Spravato |
| Avanir Pharmaceuticals, INC. | $51.38 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $46.74 | 2023 | Quviviq |
| Eisai INC. | $38.01 | 2022 | |
| Neos Therapeutics, LP | $32.58 | 2022 | |
| Almatica Pharma LLC | $20.88 | 2023 | Loreev Xr |
| Sage Therapeutics, LLC | $19.72 | 2023 | |
| Jazz Pharmaceuticals INC. | $18.53 | 2022 | |
| Noven Therapeutics, LLC | $16.92 | 2023 | Secuado |
| Axsome Therapeutics, INC. | $16.61 | 2023 | Auvelity |
| Tris Pharma INC | $16.49 | 2022 | |
| Merck Sharp & Dohme LLC | $15.56 | 2022 | |
| Arbor Pharmaceuticals, INC. | $15.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lena Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.